Dataset Fact Sheets and Datasheets


Dataset Fact Sheets and Datasheets

Published on 04/12/2025

Dataset Fact Sheets and Datasheets in AI/ML Model Validation

As the pharmaceutical industry increasingly turns to artificial intelligence (AI) and machine learning (ML) for enhancing drug development and patient care, the validation of these models under Good Automated Manufacturing Practice (GxP) guidelines has become critical. This comprehensive guide will provide a step-by-step framework for documenting and validating AI/ML models, specifically focusing on the implications of intended use, data readiness, bias and fairness, model verification and validation, and ongoing monitoring. Regulatory expectations from US FDA, EMA, and MHRA will also be discussed to ensure compliance.

1. Understanding the Regulatory Landscape for AI/ML in GxP

Before diving into the validation process, it is crucial for organizations to understand the regulatory landscape governing the use of AI/ML in pharmaceutical applications. This includes familiarizing oneself with specific regulations such as 21 CFR Part 11 in the US, which outlines the criteria for electronic records and electronic signatures. In the EU, Annex 11 provides requirements for computerized systems. The MHRA has posted guidance on the use of AI in healthcare, emphasizing the need for reliability and validation.

Key considerations include:

  • Data integrity and security
  • Documentation and audit trails
  • Technical quality of the AI/ML models
  • Risk management principles

By aligning AI/ML models with these regulations, companies can ensure that their processes conform to established standards, thereby minimizing regulatory risks.

2. Establishing Intended Use and Data Readiness

The foundation of any successful AI/ML model begins with a well-defined intended use. This concept refers to the specific purpose for which the model is being developed, which can heavily influence the design and validation aspects. Documenting the intended use clearly can help address any potential misunderstanding during validation and regulatory assessment.

Defining Intended Use

Documenting the intended use involves outlining:

  • The target population
  • The types of data the model will process
  • The decisions that will be based on model predictions

This documentation should be maintained alongside data readiness assessments that evaluate whether the data sources are reliable, accurate, and sufficient for the intended application. Data readiness involves curation, where datasets should be organized and prepared for use in training and testing the AI/ML models. Only curated and validated datasets should be used in the modeling process to maximize accuracy and relevance.

Conducting Data Readiness Reviews

Key components of data readiness include:

  • Data quality assessment
  • Data governance frameworks
  • Data preprocessing steps such as cleaning and normalization

A documentation mechanism should be established within the data readiness review process to ensure traceability and transparency. This will serve as an audit trail for any regulatory assessments.

3. Bias and Fairness Testing in AI/ML Models

As AI/ML models are increasingly used in decision-making, ensuring that their outcomes are free from bias is essential. Bias can emerge from dataset selection, model training processes, or even algorithm design. Identifying and mitigating bias is not only a regulatory requirement but also a moral obligation, especially in healthcare applications.

Implementing Fairness Metrics

Organizations should adopt various testing metrics to evaluate bias within their models, which can include:

  • Statistical parity
  • Equal opportunity
  • Calibration measures

Testing should involve diverse groups to assess the model’s performance across different demographics. This step should be clearly documented, with records maintained for any adjustments made to mitigate bias.

Establishing Bias Mitigation Frameworks

Document procedures to regularly review and update bias mitigation processes. Such frameworks exchange ongoing findings from bias testing to create a loop of continuous improvement, which also aligns with risk management principles set out by agencies such as the FDA and EMA.

4. Model Verification and Validation Processes

Model verification and validation (V&V) are crucial steps that determine whether the model meets the specified requirements under its intended use. Both processes require explicit documentation that outlines the methodologies, results, and criteria for success.

Understanding Model Verification

Verification studies must demonstrate whether the model is built correctly—evaluating aspects such as software architecture, code quality, and computational logic. Documentation for verification should include:

  • Version control logs
  • Code reviews
  • Unit tests results

Conducting Model Validation

Model validation, conversely, assesses whether the right model has been built for the designated purpose. Included documentation should illustrate:

  • Test plans
  • Performance metrics (accuracy, precision, recall)
  • Comparison against baseline models or expected performance benchmarks

The distinction between verification and validation must be effectively communicated and documented, as both stages contribute significantly to a model’s credibility.

5. Explainability (XAI) and Documentation Requirements

Explainable Artificial Intelligence (XAI) is increasingly mandatory in the pharmaceutical context as it aids end-users—be it healthcare professionals or regulatory bodies—to understand the rationale behind model predictions. An effective documentation strategy will include explainability parameters that outline how decisions were derived from the model.

Creating Explainability Reports

Documentation for explainability should encompass:

  • Model design and decision chain visualization
  • Feature importance assessments
  • Post-hoc explainability analyses (SHAP values, LIME)

These reports not only aid compliance with regulatory standards but also enhance public trust in the application of AI in healthcare.

6. Drift Monitoring and Re-Validation Protocols

Drift occurs when the statistical properties of the model’s input data change, which can lead to performance degradation over time. To mitigate this risk, organizations should establish systems to monitor for drift and re-validate models as necessary.

Implementing Drift Monitoring Systems

Documenting the need for drift detection and aligning it with the intended use encompasses:

  • Establishing thresholds for acceptable model performance levels
  • Creating alerts for performance deviations based on live data inputs
  • Routine evaluations of input data quality

Re-Validation Documentation

The re-validation process must be thoroughly documented, indicating how and when models were re-validated, the rationale for doing so, and the outcomes. Reports should reflect changes made to the model and its implications for performance and regulatory compliance.

7. Ensuring Compliance with Governance and Security Practices

Governance and security practices are critical in managing the complexities introduced by AI/ML technologies. Organizations must foster a culture of accountability while ensuring that robust governance protocols are in place to adhere to regulatory requirements.

Creating Governance Frameworks

Strong governance practices must include comprehensive policies on:

  • Data access and authorization levels
  • Risk assessment frameworks
  • Training protocols for users operating AI/ML systems

This documentation should be readily accessible and continuously updated to reflect the evolving technological landscape.

Security Measures and Documentation

Documentation of security practices should encompass methods for protecting data integrity, confidentiality, and providing an audit trail. Regular security audits should be conducted, with findings formally documented and issues addressed within specified timelines.

Conclusion

In summary, as the pharmaceutical industry integrates AI/ML technologies into its processes, developing a systematic and compliant approach to documentation, verification, validation, and governance is essential. By following the steps outlined in this guide, organizations can align their practices with the regulatory expectations of the US FDA, EMA, and MHRA, thereby fostering a safe and effective use of innovative technologies in healthcare. Adopting these practices not only ensures compliance but also enhances the reliability and trustworthiness of AI/ML applications in the pharmaceutical sector.